{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-031008","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.218326+00:00","generated_at":"2026-06-06T04:29:54.229966+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AN2 Therapeutics pauses Phase 3 enrollment in epetraborole trial after efficacy concern","bullets":["Voluntary pause of Phase 3 enrollment in EBO-301 trial for treatment-refractory MAC lung disease.","Blinded aggregate analysis showed potentially lower than expected efficacy; no safety concerns cited.","Phase 2 part completed enrollment with 80 patients; Phase 3 had enrolled nearly 100 patients to date.","Enrolled patients allowed to continue; topline Phase 2 data expected summer 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-031008","json":"https://secwatch.observer/filing/0001193125-24-031008.json","markdown":"https://secwatch.observer/filing/0001193125-24-031008.md","text":"https://secwatch.observer/filing/0001193125-24-031008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524031008/0001193125-24-031008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524031008/d744326d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:29:54.229966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}